Wegovy-maker Novo Nordisk sales soar 30% on strong demand for its weight-loss drug

A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. 

Jim Vondruska | Reuters

Novo Nordisk, which makes the weight-loss drug Wegovy, raised its outlook for 2023 Thursday, as it reported soaring sales.

The Danish pharmaceutical company reported a 30% increase in sales (at constant exchange rates) for the first half of this year, while operating profit also rose 32%.

Its diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injections Wegovy and Ozempic.

“The [sales] growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before,” Lars Fruergaard Jørgensen, president and CEO, said in a statement. “The performance in the first six months has enabled us to raise the outlook for the full year.”

Shares are up almost 1% in pre-market trading.

This is a developing story and will be updated shortly.


Source link

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top